RU2010106975A - Бициклические амиды для усиления глутаматергических синаптических ответов - Google Patents
Бициклические амиды для усиления глутаматергических синаптических ответов Download PDFInfo
- Publication number
- RU2010106975A RU2010106975A RU2010106975/04A RU2010106975A RU2010106975A RU 2010106975 A RU2010106975 A RU 2010106975A RU 2010106975/04 A RU2010106975/04 A RU 2010106975/04A RU 2010106975 A RU2010106975 A RU 2010106975A RU 2010106975 A RU2010106975 A RU 2010106975A
- Authority
- RU
- Russia
- Prior art keywords
- substituted
- unsubstituted
- compound according
- compound
- patient
- Prior art date
Links
- 150000001408 amides Chemical class 0.000 title 1
- 230000000848 glutamatergic effect Effects 0.000 title 1
- 238000005728 strengthening Methods 0.000 title 1
- 230000000946 synaptic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 37
- 125000000217 alkyl group Chemical group 0.000 claims abstract 9
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 9
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 3
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 3
- 125000003118 aryl group Chemical group 0.000 claims abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000004181 carboxyalkyl group Chemical group 0.000 claims abstract 3
- 125000005026 carboxyaryl group Chemical group 0.000 claims abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract 3
- 150000002367 halogens Chemical class 0.000 claims abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 3
- 239000001301 oxygen Substances 0.000 claims abstract 3
- 125000004963 sulfonylalkyl group Chemical group 0.000 claims abstract 3
- 239000011593 sulfur Substances 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 12
- 238000004519 manufacturing process Methods 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 102000003678 AMPA Receptors Human genes 0.000 claims 4
- 108090000078 AMPA Receptors Proteins 0.000 claims 4
- 230000007812 deficiency Effects 0.000 claims 4
- 230000002964 excitative effect Effects 0.000 claims 4
- 230000003528 hypoglutamatergic effect Effects 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 210000000225 synapse Anatomy 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- VLWZXHFZCBBXDR-UHFFFAOYSA-N 2,1,3-benzoxadiazol-5-yl-(3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C2CCC1CC(O)C2 VLWZXHFZCBBXDR-UHFFFAOYSA-N 0.000 claims 2
- -1 2-azabicyclo [2.2.1] hept-2-yl Chemical group 0.000 claims 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000006289 Rett Syndrome Diseases 0.000 claims 2
- 210000001766 X chromosome Anatomy 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 230000006399 behavior Effects 0.000 claims 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 230000001054 cortical effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- JSXFREXUMJSKSB-UHFFFAOYSA-N 1-(2,1,3-benzoxadiazol-5-yl)octan-1-one Chemical compound C(CCCCCC)C(=O)C1=CC=2C(=NON=2)C=C1 JSXFREXUMJSKSB-UHFFFAOYSA-N 0.000 claims 1
- ICPFDEGHIWLQHT-UHFFFAOYSA-N 2,1,3-benzoxadiazol-5-yl(2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C(CO2)CC2C1 ICPFDEGHIWLQHT-UHFFFAOYSA-N 0.000 claims 1
- VLJBTMQPNFWPHP-UHFFFAOYSA-N 2,1,3-benzoxadiazol-5-yl-(2,3-dichloro-5-azabicyclo[2.2.1]heptan-5-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N(C1)C2CC1C(Cl)C2Cl VLJBTMQPNFWPHP-UHFFFAOYSA-N 0.000 claims 1
- QMYRVTKSHZXAMU-UHFFFAOYSA-N 2,1,3-benzoxadiazol-5-yl-(3,3-difluoro-8-azabicyclo[3.2.1]octan-8-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C2CCC1CC(F)(F)C2 QMYRVTKSHZXAMU-UHFFFAOYSA-N 0.000 claims 1
- OWSSSZMWGUEXGU-UHFFFAOYSA-N 2,1,3-benzoxadiazol-5-yl-(3-fluoro-8-azabicyclo[3.2.1]oct-3-en-8-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C2CCC1C=C(F)C2 OWSSSZMWGUEXGU-UHFFFAOYSA-N 0.000 claims 1
- GQXWPOIQMPNUNL-UHFFFAOYSA-N 3-azabicyclo[2.2.2]octan-3-yl(2,1,3-benzoxadiazol-5-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C(CC2)CCC2C1 GQXWPOIQMPNUNL-UHFFFAOYSA-N 0.000 claims 1
- XLCOYPYTNJSQFB-UHFFFAOYSA-N 5-azabicyclo[2.2.1]hept-2-en-5-yl(2,1,3-benzoxadiazol-5-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C(C=C2)CC2C1 XLCOYPYTNJSQFB-UHFFFAOYSA-N 0.000 claims 1
- FLBFCCXBAQITHK-UHFFFAOYSA-N 8-(2,1,3-benzoxadiazole-5-carbonyl)-8-azabicyclo[3.2.1]octan-3-one Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C2CCC1CC(=O)C2 FLBFCCXBAQITHK-UHFFFAOYSA-N 0.000 claims 1
- JMXIVHHAHKCDSZ-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octan-8-yl(2,1,3-benzoxadiazol-5-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1C2CCC1CCC2 JMXIVHHAHKCDSZ-UHFFFAOYSA-N 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- XLCOYPYTNJSQFB-HTLJXXAVSA-N [(4r)-5-azabicyclo[2.2.1]hept-2-en-5-yl]-(2,1,3-benzoxadiazol-5-yl)methanone Chemical compound C1=CC2=NON=C2C=C1C(=O)N1[C@@H](C=C2)CC2C1 XLCOYPYTNJSQFB-HTLJXXAVSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96436207P | 2007-08-10 | 2007-08-10 | |
| US60/964,362 | 2007-08-10 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010107795/15A Division RU2010107795A (ru) | 2007-08-10 | 2010-03-04 | Бициклические амиды для усиления глутаматергических синаптических ответов |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010106975A true RU2010106975A (ru) | 2011-09-20 |
Family
ID=40351347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010106975/04A RU2010106975A (ru) | 2007-08-10 | 2008-08-08 | Бициклические амиды для усиления глутаматергических синаптических ответов |
| RU2010107795/15A RU2010107795A (ru) | 2007-08-10 | 2010-03-04 | Бициклические амиды для усиления глутаматергических синаптических ответов |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010107795/15A RU2010107795A (ru) | 2007-08-10 | 2010-03-04 | Бициклические амиды для усиления глутаматергических синаптических ответов |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8263591B2 (enExample) |
| EP (1) | EP2187888B1 (enExample) |
| JP (2) | JP5576277B2 (enExample) |
| KR (2) | KR20100045507A (enExample) |
| CN (2) | CN101862330A (enExample) |
| AU (2) | AU2008287445A1 (enExample) |
| BR (2) | BRPI0814149A2 (enExample) |
| CA (2) | CA2702292A1 (enExample) |
| ES (1) | ES2560095T3 (enExample) |
| MX (2) | MX2010001630A (enExample) |
| NZ (1) | NZ583823A (enExample) |
| RU (2) | RU2010106975A (enExample) |
| SG (1) | SG163526A1 (enExample) |
| WO (1) | WO2009023126A2 (enExample) |
| ZA (1) | ZA201001691B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2502A (en) | 2007-01-03 | 2012-10-23 | Servier Lab | 3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses |
| KR101599661B1 (ko) | 2007-05-17 | 2016-03-03 | 코텍스 파마슈티칼스, 인크. | 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물 |
| BRPI0814149A2 (pt) | 2007-08-10 | 2011-09-13 | Cortex Pharma Inc | composto, composição farmacêutica, métodos de tratamento e uso do composto |
| US8168632B2 (en) | 2007-08-10 | 2012-05-01 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for the treatment of respiratory disorders |
| BRPI1005316A2 (pt) * | 2009-02-02 | 2019-09-24 | Cortex Pharma Inc | composto, composição farmacêuttca, métodos para tratamento e uso de um composto |
| EP2811997B1 (en) | 2012-02-07 | 2018-04-11 | Eolas Therapeutics Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| WO2016025669A1 (en) | 2014-08-13 | 2016-02-18 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
| US9739787B2 (en) | 2015-09-01 | 2017-08-22 | Abdulmohsen Ebrahim Alterki | Method for diagnosing sleep apnea by measuring adipsin and betatrophin levels |
| PL3414241T3 (pl) | 2016-02-12 | 2022-10-03 | Astrazeneca Ab | Piperydyny podstawione halo jako modulatory receptora oreksyny |
| WO2018009256A1 (en) * | 2016-03-29 | 2018-01-11 | Respirerx Pharmaceuticals, Inc. | Compositions and methods for treating attention deficit disorders |
| KR20220016918A (ko) | 2019-06-04 | 2022-02-10 | 하거 바이오사이언시즈, 엘엘씨 | 오렉신 길항제로서의 이미다졸로 유도체, 조성물 및 방법 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3723436A (en) * | 1971-02-25 | 1973-03-27 | Sun Oil Co | Process for aromatic lactams |
| FR2597103B1 (fr) * | 1986-04-15 | 1988-12-16 | Provesan Sa | Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde |
| DK1156043T3 (da) | 1992-07-24 | 2004-03-01 | Univ California | Lægemidler, der forøger synaptiske reaktioner formidlet af ampa-receptorer |
| US20020099050A1 (en) * | 1993-07-23 | 2002-07-25 | Lynch Gary S. | Drugs that enhance synaptic responses mediated by AMPA receptors |
| US5650409A (en) * | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5736543A (en) * | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| US6030968A (en) * | 1996-09-17 | 2000-02-29 | The Regents Of The University Of California | Positive AMPA receptor modulation to enhance brain neurotrophic factor expression |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| CN1281335A (zh) * | 1997-10-27 | 2001-01-24 | 科泰克斯药物股份有限公司 | 用安哌克和精神安定剂治疗精神分裂症 |
| US5985871A (en) | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| WO1999042456A2 (en) | 1998-02-18 | 1999-08-26 | Neurosearch A/S | Novel compounds and their use as positive ampa receptor modulators |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6303542B1 (en) * | 2000-08-18 | 2001-10-16 | Rohm And Haas Company | Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones |
| PA8535601A1 (es) * | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| AUPS255202A0 (en) | 2002-05-27 | 2002-06-13 | Monash University | Agents and methods for the treatment of disorders associated with motor neuron degeneration |
| WO2004089416A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| US20050085446A1 (en) | 2003-04-14 | 2005-04-21 | Babu M.K. M. | Fluoroquinolone formulations and methods of making and using the same |
| GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| CA2660431C (en) | 2006-08-31 | 2015-03-17 | The Governors Of The University Of Alberta | Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators |
| US20100041647A1 (en) * | 2007-01-03 | 2010-02-18 | Cortex Pharmaceuticals, Inc. | 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses |
| AP2502A (en) | 2007-01-03 | 2012-10-23 | Servier Lab | 3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses |
| KR101599661B1 (ko) * | 2007-05-17 | 2016-03-03 | 코텍스 파마슈티칼스, 인크. | 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물 |
| BRPI0814149A2 (pt) | 2007-08-10 | 2011-09-13 | Cortex Pharma Inc | composto, composição farmacêutica, métodos de tratamento e uso do composto |
| BRPI0815957A2 (pt) | 2007-09-20 | 2019-09-24 | Cortex Pharma Inc | "composto, composição farmacêutica, métodos e respectivo uso de 1,2,3-triazin-4-onas trissubstituídas e 1,3-pirimidinonas trissubstituídas para a melhora das respostas sinápticas glutamatérgicas" |
-
2008
- 2008-08-08 BR BRPI0814149-5A patent/BRPI0814149A2/pt not_active IP Right Cessation
- 2008-08-08 AU AU2008287445A patent/AU2008287445A1/en not_active Abandoned
- 2008-08-08 CA CA2702292A patent/CA2702292A1/en not_active Abandoned
- 2008-08-08 KR KR1020107005366A patent/KR20100045507A/ko not_active Withdrawn
- 2008-08-08 EP EP08795126.5A patent/EP2187888B1/en active Active
- 2008-08-08 NZ NZ583823A patent/NZ583823A/en not_active IP Right Cessation
- 2008-08-08 SG SG201004604-3A patent/SG163526A1/en unknown
- 2008-08-08 WO PCT/US2008/009508 patent/WO2009023126A2/en not_active Ceased
- 2008-08-08 CN CN201010207140A patent/CN101862330A/zh active Pending
- 2008-08-08 BR BRPI0823262-8A2A patent/BRPI0823262A2/pt not_active Application Discontinuation
- 2008-08-08 RU RU2010106975/04A patent/RU2010106975A/ru not_active Application Discontinuation
- 2008-08-08 US US12/733,073 patent/US8263591B2/en not_active Expired - Fee Related
- 2008-08-08 MX MX2010001630A patent/MX2010001630A/es unknown
- 2008-08-08 JP JP2010520992A patent/JP5576277B2/ja not_active Expired - Fee Related
- 2008-08-08 CA CA2695742A patent/CA2695742C/en not_active Expired - Fee Related
- 2008-08-08 KR KR1020107004015A patent/KR20100051678A/ko not_active Ceased
- 2008-08-08 ES ES08795126.5T patent/ES2560095T3/es active Active
- 2008-08-08 CN CN2008801025333A patent/CN101896183B/zh not_active Expired - Fee Related
- 2008-08-08 MX MX2010001631A patent/MX2010001631A/es active IP Right Grant
-
2010
- 2010-02-17 AU AU2010200563A patent/AU2010200563A1/en not_active Abandoned
- 2010-03-04 RU RU2010107795/15A patent/RU2010107795A/ru not_active Application Discontinuation
- 2010-03-09 ZA ZA2010/01691A patent/ZA201001691B/en unknown
- 2010-04-21 JP JP2010098175A patent/JP2010215630A/ja active Pending
- 2010-09-03 US US12/807,379 patent/US8110584B2/en not_active Expired - Fee Related
-
2012
- 2012-07-25 US US13/557,681 patent/US9492440B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010106975A (ru) | Бициклические амиды для усиления глутаматергических синаптических ответов | |
| TW200932236A (en) | Aryl-substituted bridged diamines as modulators of leukotriene A4 hydrolase | |
| TWI343385B (en) | Fused bicycloheterocycle substituted azabicyclic alkane derivatives | |
| JP2010535858A5 (enExample) | ||
| SU1676451A3 (ru) | Способ получени производных бензимидазола в виде смеси изомеров или индивидуальных изомеров в свободном виде или в виде их физиологически приемлемых солей | |
| ES2383001T3 (es) | Compuestos de heteroarilo condensado sustituidos con azabicíclico para el tratamiento de enfermedades | |
| ES2204711T3 (es) | Acrilamidas de quinuclidina. | |
| EP4301363A1 (en) | Quinazoline amine derivatives as kras inhibitors | |
| JP5512268B2 (ja) | ５ｈｔ３モジュレーターとしての２−アミノベンゾオキサゾールカルボキサミド | |
| JP5675943B2 (ja) | ロイコトリエンａ４加水分解酵素の調節因子としてのチアゾロピリジン−２−イルオキシ−フェニル及びチアゾロピラジン−２−イルオキシ−フェニルアミン | |
| BRPI0711941A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| MX2010012807A (es) | Moduladores del rceptor 5-hidroxitriptamina 3, metodos de fabricacion y uso de los mismos. | |
| JP2010513434A5 (enExample) | ||
| JP2006506395A (ja) | ＣＮＳ疾患の治療のための、α７ニコチンアゴニスト活性及び５ＨＴ３アンタゴニスト活性を有する化合物 | |
| JP5746685B2 (ja) | ロイコトリエンａ４加水分解酵素のモジュレーターとしての縮合二環式ヘテロアリール部分を２つ有する化合物 | |
| PT1397366E (pt) | Novo ligando para os receptores nicotínicos da acetilcolina úteis em terapia | |
| CA3147105A1 (en) | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea | |
| DE602005008633D1 (de) | Imidazoä1,5aütriazoloä1,5dübenzodiazepin-derivative zur behandlung kognitiver störungen | |
| ES2218930T3 (es) | Nuevos derivados basicos de benzo(e)isoindol-1-onas y pirrolo(3,4-c)quinolin-1-onas con actividas antagonista de 5-ht3, su preparacion y su uso terapeutico. | |
| Langlois et al. | Derivatives of naphthalimide: new potent conformationally restricted antagonists of 5-HT3 receptors. | |
| SG185969A1 (en) | Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder | |
| JPH0232077A (ja) | ベンゾフランおよびベンゾピラン化合物 | |
| CN118434415A (zh) | 用于治疗睡眠呼吸暂停的task1/3通道阻断剂与毒蕈碱型受体拮抗剂的结合物 | |
| CN119923400A (zh) | Abhd6拮抗剂 | |
| ZA200402171B (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130624 |